TD Cowen analyst Joseph Thome maintained a Hold rating on PTC Therapeutics (PTCT – Research Report) today and set a price target of $50.00. The ...

Investors and market watchers will likely monitor PTC Therapeutics (NASDAQ:PTCT) closely to see if the company's performance aligns with Cowen's projections and to gauge the potential impact of this ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned a consensus rating of “Hold” from the fifteen research ...

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from William Blair analyst Sami Corwin today. The ...

Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for PTC Therapeutics in a report ...

WARREN, N.J. - PTC Therapeutics, Inc. (NASDAQ: NASDAQ:PTCT), a biopharmaceutical company with a market capitalization of $3.4 billion and an impressive 60.8% stock return over... ByInvesting.com ...

Check the time stamp on this data. Updated AI-Generated Signals for Ptc Therapeutics Inc. (PTCT) available here: PTCT. Type a ...

PTC Therapeutics has demonstrated strong financial performance in recent quarters, consistently beating revenue expectations. In the third quarter of 2024, the company reported a total revenue beat of ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...